Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
112 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016', provides in depth analysis on Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted pipeline therapeutics. The report provides comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects - The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Overview 9 Therapeutics Development 10 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Stage of Development 10 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Therapy Area 11 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Indication 12 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Companies 17 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Universities/Institutes 21 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development 30 Aduro BioTech, Inc. 30 Agenus, Inc. 31 Alligator Bioscience AB 32 AlphaMab Co., Ltd 33 Bristol-Myers Squibb Company 34 Cold Genesys, Inc. 35 CytomX Therapeutics, Inc. 36 Immunocore Limited 37 JHL Biotech, Inc. 38 Lytix Biopharma AS 39 MedImmune, LLC 40 Novartis AG 41 OncoImmune, Inc. 42 Premier Biomedical Inc 43 PsiOxus Therapeutics Limited 44 Sutro Biopharma, Inc. 45 Theravectys SA 46 Tikcro Technologies, Ltd. 47 Xencor, Inc. 48 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles 49 AGEN-1884 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 AGEN-2041 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Antisense Oligonucleotide to Inhibit CTLA4 for Oncology - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 ATOR-1015 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Biologic to Antagonize CTLA4 for Solid Tumor - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 CG-0070IT - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 CG-0161 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 durvalumab + IMCgp-100 + tremelimumab - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 durvalumab + tremelimumab - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 ipilimumab - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 JMW-3B3 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 KN-044 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 LTX-315 + Anti-CTLA4 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 MEDI-0562 + tremelimumab - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 MEDI-3617 + tremelimumab - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Monoclonal Antibodies to Inhibit CTLA-4 for Metastatic Melanoma - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Monoclonal Antibody to Antagonize CTLA-4 for Oncology - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Monoclonal Antibody to Inhibit CTLA-4 for Oncology - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Monoclonal Antibody to Inhibit CTLA4 for Breast Cancer - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 Monoclonal Antibody to Inhibit CTLA4 for Oncology - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 ONC-392 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Oncolytic Viruses to Antagonize CTLA4 for Solid Tumors - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 SNCA-21 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 tremelimumab - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 XmAb-20717 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Projects 93 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products 95 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Featured News & Press Releases 96 Oct 08, 2016: Yervoy (ipilimumab) Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study 96 Sep 06, 2016: Mesothelioma Treatment Center at Baylor St. Luke's launches clinical trial of cancer combination therapy 97 Jul 27, 2016: Combining Ipilimumab with local treatments improved survival for patients with melanoma 98 Jul 13, 2016: Immunotherapy benefits relapsed stem cell transplant recipients 99 Apr 27, 2016: Agenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors 100 Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate AGEN2041 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 101 Feb 29, 2016: AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma 102 Feb 17, 2016: Immune-targeting drug combo shows promise for lung cancer patients, says Moffitt 102 Feb 08, 2016: Astrazeneca'S Combination of Durvalumab with Tremelimumab Shows Clinical Activity in Non-Small Cell Lung Cancer Irrespective Of PD-L1 Status 103 Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-CTLA-4 Antibody 104 Oct 28, 2015: Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma 105 Oct 19, 2015: Cold Genesys Announces FDA Acceptance of a Phase I/II Clinical Trial Using CG0070 Plus an Anti-CTLA-4 Checkpoint Inhibitor as a Neo-Adjuvant Immunotherapy for Muscle Invasive Bladder Cancer 106 Jun 02, 2015: AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015 107 May 31, 2015: Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo + Yervoy Regimen or Opdivo Monotherapy vs. Yervoy Monotherapy in Previously Untreated Patients with Advanced Melanoma 108 Appendix 111 Methodology 111 Coverage 111 Secondary Research 111 Primary Research 111 Expert Panel Validation 111 Contact Us 111 Disclaimer 112
List of Tables
Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Indication, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Early Stage Products, H2 2016 15 Comparative Analysis by Unknown Stage Development, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Development by Companies, H2 2016 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2016 21 Products under Investigation by Universities/Institutes, H2 2016 22 Assessment by Monotherapy/Combination Products, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Pipeline by Aduro BioTech, Inc., H2 2016 30 Pipeline by Agenus, Inc., H2 2016 31 Pipeline by Alligator Bioscience AB, H2 2016 32 Pipeline by AlphaMab Co., Ltd, H2 2016 33 Pipeline by Bristol-Myers Squibb Company, H2 2016 34 Pipeline by Cold Genesys, Inc., H2 2016 35 Pipeline by CytomX Therapeutics, Inc., H2 2016 36 Pipeline by Immunocore Limited, H2 2016 37 Pipeline by JHL Biotech, Inc., H2 2016 38 Pipeline by Lytix Biopharma AS, H2 2016 39 Pipeline by MedImmune, LLC, H2 2016 40 Pipeline by Novartis AG, H2 2016 41 Pipeline by OncoImmune, Inc., H2 2016 42 Pipeline by Premier Biomedical Inc, H2 2016 43 Pipeline by PsiOxus Therapeutics Limited, H2 2016 44 Pipeline by Sutro Biopharma, Inc., H2 2016 45 Pipeline by Theravectys SA, H2 2016 46 Pipeline by Tikcro Technologies, Ltd., H2 2016 47 Pipeline by Xencor, Inc., H2 2016 48 Dormant Projects, H2 2016 93 Dormant Projects (Contd..1), H2 2016 94 Discontinued Products, H2 2016 95
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
